| The Lausanne Branch focuses primarily on tumor immunology and immunotherapy. This includes the mechanisms by which tumors thwart immune attack and the development of novel immunotherapies, especially those in which the treatment is tailored to a patient's cancer-such as dendritic cell vaccines and therapies that involve the manipulation and reinfusion of a patient's T cells. We also focus on developing technologies to standardize and streamline such personalized therapies, which will be essential to their wider deployment. |
